|
US2009042847A1
|
|
17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
|
|
US2008319211A1
|
|
Process for the preparation of epothilones
|
|
WO2008141130A1
|
|
Process for the preparation of epothilones
|
|
JP2008169226A
|
|
Combinatorial polyketide libraries produced using a modular pks gene cluster as scaffold
|
|
CN101711154A
|
|
carbamate compounds
|
|
EP2121957A1
|
|
Macrolactams by engineered biosynthesis
|
|
US2007265333A1
|
|
Macrocyclic kinase inhibitors
|
|
AU2007200160A1
|
|
Heterologous production of polyketides
|
|
WO2007084233A2
|
|
Pharmaceutical formulations comprising 17-allylamino-17-demethoxygeldanamycin
|
|
US2008096828A1
|
|
7-quinolyl ketolide antibacterial agents
|
|
CN101578267A
|
|
17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
|
|
KR20080081249A
|
|
Method of treating breast cancer using 17-aag or 17-ag 0r a prodrug of either in combination with a her2 inhibitor
|
|
CN101528705A
|
|
Method of treating breast cancer using 17-aag or 17-ag or a prodrug of either in combination with a her2 inhibitor
|
|
WO2007033214A2
|
|
Esters of compounds in the leptomycin family
|
|
WO2008020830A1
|
|
Method of treating an aspergillus or cryptococcus infection by administering ambruticin vs-3, vs-4, or vs-5
|
|
WO2006124358A2
|
|
Method of treating a coccidioides infection by administering an ambruticin compound
|
|
CA2604424A1
|
|
Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor
|
|
CN101166526A
|
|
Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
|
|
US2006252739A1
|
|
Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either
|
|
EP1853238A2
|
|
Pharmaceutical formulations containing 17-allylamino-17-demethoxygeldanamycin
|
